AXGN

Business Context and Reporting Period

This Form 10-QX is filed by LecTec Corporation (not Axogen, Inc.) for the quarterly period ended March 31, 1996. The company operates in the medical products sector, with primary product groups including conductive products, medical tapes, and therapeutic products. The filing covers the third quarter and the first nine months of fiscal year 1996.

Key Financial Metrics

Material Changes Versus Prior Period

• Revenue Decline: Q3 revenues decreased 9.9% year-over-year, driven by a 14.5% drop in medical tape sales and a 44.6% drop in therapeutic product sales. These declines were partially offset by a 15.2% increase in conductive product sales.
• Profitability Shift: While the company remained profitable in Q3, it reported a net loss of $616,654 for the nine-month period, compared to a net income of $302,810 in the prior year. This reversal was primarily due to a $300,000 loss on the disposal of assets and increased R&D expenses.
• Margin Compression: Gross margins declined from 41.0% to 38.6% in Q3, attributed to the reduced mix of higher-margin therapeutic products and increased raw material costs.
• Expense Fluctuations: Selling, general, and administrative (SG&A) expenses decreased in Q3 due to the divestiture of direct marketing assets, but increased for the nine-month period due to costs associated with that divestiture and subsidiary operations. R&D expenses rose significantly due to development of a non-nicotine smoking cessation product and pain patch program.
• Liquidity Reduction: Cash and cash equivalents dropped from $839,942 to $229,852 over the nine-month period, reflecting a net cash outflow from operating activities of $409,460 and investing activities of $386,894.

Guidance, Outlook, and Risks

• Strategic Divestiture: The company completed the sale of direct marketing-related assets of its Pharmadyne subsidiary during the quarter. This action reduced SG&A expenses in the current quarter but resulted in a significant one-time loss.
• Capital Expenditures: Management estimates capital expenditures will approach $400,000 for fiscal 1996, primarily for equipment and improvements, to be financed by operations.
• Liquidity Position: The company maintains a $1,000,000 line of credit. While the current ratio remains strong at 3.24, working capital has decreased. The company has no long-term debt.
• Tax Implications: No tax benefit was recorded for the nine-month losses as they relate primarily to the Pharmadyne subsidiary and cannot be utilized by the parent company at this time.
• Risks: Continued reliance on specific product lines (conductive products) to offset declines in others (therapeutic and tape). The success of new R&D initiatives (smoking cessation, pain patches) is critical for future growth.

Investor Verification Checklist

• Verify the impact of the Pharmadyne subsidiary asset sale on future revenue streams and recurring expenses.
• Confirm the timeline and expected revenue contribution of the new non-nicotine smoking cessation product and pain patch program.
• Assess the sustainability of the 15.2% growth in conductive product sales given the decline in other major categories.
• Monitor cash burn rate and the utilization of the $1,000,000 line of credit given the significant decrease in cash reserves.
• Review the status of the major tape converter order mentioned as absent in the current year to determine if it is a permanent loss of business.